Data Sheet 1_Valve-in-valve transcatheter aortic valve replacement (TAVR) leads to lower device success compared to TAVR in native stenosis.pdf by Michael Paukovitsch (16428786)

“…The overall rate of device success amounted to 66% in ViV-TAVR, compared to 96.1% in TAVR (p < 0.01) and ViV-TAVR was independently associated with reduced device success (OR: 0.07, 95%CI: 0.045–0.12, p < 0.01) in multivariate regression. While ViV-TAVR decreased peak and mean gradients significantly, in 31% of patients elevated mean gradients (≥20 mmHg) were observed at discharge. …”

Effects of MC treatment on symptoms and histological changes in DNBS-induced colitis rats. by Jin-Hwa Kim (101817)

Immunohistochemical staining results for OMP in olfactory bulb. by Myeongguk Jeong (16386165)

Comparison of SD method scores between three ECDs (<i>n</i> = 34; *<i>p</i> < 0.05 using Friedman test with Bonferroni’s correction). by Yong-Rae Kim (19797278)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Comparison of six theoretical mood factors and TMD scores estimated using K-POMS-B between three ECDs (<i>n</i> = 34; *<i>p</i> < 0.05 using Friedman test with Bonferroni’s correct... by Yong-Rae Kim (19797278)

Olfactory function test graphical summary and results. by Myeongguk Jeong (16386165)

Fig 3 - by Yong-Rae Kim (19797278)

Fig 4 - by Yong-Rae Kim (19797278)

Fig 5 - by Yong-Rae Kim (19797278)

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

¹H NMR spectra for kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

“…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …”